LT3290441T - Rgma surišantys baltymai ir jų panaudojimas - Google Patents

Rgma surišantys baltymai ir jų panaudojimas

Info

Publication number
LT3290441T
LT3290441T LTEP16786512.0T LT16786512T LT3290441T LT 3290441 T LT3290441 T LT 3290441T LT 16786512 T LT16786512 T LT 16786512T LT 3290441 T LT3290441 T LT 3290441T
Authority
LT
Lithuania
Prior art keywords
binding protein
rgma binding
rgma
protein
binding
Prior art date
Application number
LTEP16786512.0T
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Osaka University
National University Corporation Chiba University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation, Osaka University, National University Corporation Chiba University filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of LT3290441T publication Critical patent/LT3290441T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
LTEP16786512.0T 2015-04-28 2016-04-27 Rgma surišantys baltymai ir jų panaudojimas LT3290441T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28
PCT/JP2016/063166 WO2016175236A1 (ja) 2015-04-28 2016-04-27 ＲＧＭａ結合タンパク質及びその使用

Publications (1)

Publication Number Publication Date
LT3290441T true LT3290441T (lt) 2020-02-10

Family

ID=57198582

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16786512.0T LT3290441T (lt) 2015-04-28 2016-04-27 Rgma surišantys baltymai ir jų panaudojimas

Country Status (34)

Country Link
US (3) US10287346B2 (lt)
EP (2) EP3584260A1 (lt)
JP (6) JP6497760B2 (lt)
KR (4) KR102040235B1 (lt)
CN (2) CN113801225A (lt)
AU (2) AU2016253886B2 (lt)
BR (1) BR112017022994A2 (lt)
CA (1) CA2983898A1 (lt)
CL (1) CL2017002729A1 (lt)
CO (1) CO2017011975A2 (lt)
CR (2) CR20200517A (lt)
CY (1) CY1122569T1 (lt)
DK (1) DK3290441T3 (lt)
DO (1) DOP2017000248A (lt)
ES (1) ES2758480T3 (lt)
GT (1) GT201700224A (lt)
HK (1) HK1245808A1 (lt)
HR (1) HRP20192099T1 (lt)
HU (1) HUE047146T2 (lt)
IL (2) IL287291B (lt)
LT (1) LT3290441T (lt)
MX (2) MX2017013894A (lt)
PE (2) PE20230381A1 (lt)
PH (1) PH12017501941A1 (lt)
PL (1) PL3290441T3 (lt)
PT (1) PT3290441T (lt)
RS (1) RS59847B1 (lt)
RU (1) RU2705304C2 (lt)
SA (1) SA517390230B1 (lt)
SG (1) SG11201708848TA (lt)
SI (1) SI3290441T1 (lt)
TW (3) TWI732757B (lt)
WO (1) WO2016175236A1 (lt)
ZA (2) ZA201708047B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200517A (es) * 2015-04-28 2021-01-12 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNION A RGma Y SUS USO
US11035534B2 (en) 2017-05-25 2021-06-15 Signify Holding B.V. Luminaire
CN112533635A (zh) 2018-07-10 2021-03-19 田边三菱制药株式会社 末梢神经病变或者伴随确认到末梢神经病变或星形胶质细胞病变的疾病的疼痛的预防或治疗方法
JP7150286B2 (ja) * 2018-07-19 2022-10-11 国立大学法人 東京大学 Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
US20230090965A1 (en) 2020-01-15 2023-03-23 Osaka University Prophylactic or therapeutic agent for dementia
EP4091632A1 (en) 2020-01-15 2022-11-23 Osaka University Agent for prevention or treatment of diabetic autonomic neuropathy
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
WO2024101345A1 (ja) * 2022-11-07 2024-05-16 国立大学法人大阪大学 異常タンパク質の凝集体蓄積が関与する疾患の予防又は治療剤

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
JP2001515018A (ja) 1997-08-13 2001-09-18 エール ユニバーシティ 中枢神経軸索再生
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000032746A2 (en) 1998-11-30 2000-06-08 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
WO2002063959A1 (en) 2001-02-09 2002-08-22 The Schepens Eye Research Institute Methods and compositions for stimulating axon regeneration and prventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1490108A4 (en) 2002-04-18 2006-08-09 Gen Hospital Corp DRAG11 GENERAL FAMILY (DRAGON)
US7771952B2 (en) 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
EP1733737A4 (en) 2004-03-11 2007-09-05 Bioclues Inc AXON REGENERATION PROMOTER
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
WO2006019904A1 (en) 2004-07-14 2006-02-23 University Of Utha Research Foundation Netrin-related compositions and uses
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
JPWO2008038599A1 (ja) 2006-09-25 2010-01-28 国立大学法人 千葉大学 軸索再生促進剤
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
EP2502623B1 (en) 2008-06-06 2016-04-06 Children's Medical Center Corporation Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation
JP2010146801A (ja) 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
BR112012013734A2 (pt) * 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
CN102811739A (zh) 2009-12-09 2012-12-05 田边三菱制药株式会社 T细胞活化抑制剂、含有其的药物组合物以及抑制t细胞活化的物质的筛选方法
WO2013090635A2 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
BR112015023862A2 (pt) * 2013-03-18 2017-10-24 Biocerox Prod Bv anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado
KR20160055275A (ko) 2013-09-17 2016-05-17 유니버시티 헬스 네트워크 시스 ｒｇｍａ/네오제닌 상호작용 또는 지질 래프트에 대해 지시되는 제제 및 치료 방법에서의 이의 용도
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CR20200517A (es) * 2015-04-28 2021-01-12 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNION A RGma Y SUS USO
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA

Also Published As

Publication number Publication date
KR20170138565A (ko) 2017-12-15
SA517390230B1 (ar) 2021-06-09
US20180100012A1 (en) 2018-04-12
IL287291B (en) 2022-09-01
US20210277098A1 (en) 2021-09-09
SI3290441T1 (sl) 2020-03-31
RU2017135353A (ru) 2019-04-08
RU2017135353A3 (lt) 2019-04-08
CN107531791B (zh) 2021-09-07
US10287346B2 (en) 2019-05-14
JP2021106587A (ja) 2021-07-29
PH12017501941A1 (en) 2018-03-19
AU2019210655A1 (en) 2019-08-22
JP2023030057A (ja) 2023-03-07
KR102040235B1 (ko) 2019-11-05
IL255293A0 (en) 2017-12-31
DOP2017000248A (es) 2018-01-31
EP3584260A1 (en) 2019-12-25
EP3290441A4 (en) 2018-10-17
AU2016253886B2 (en) 2019-05-16
KR102613528B1 (ko) 2023-12-12
ZA201907773B (en) 2021-05-26
MX2022005565A (es) 2022-06-09
HK1245808A1 (zh) 2018-08-31
CO2017011975A2 (es) 2018-02-20
RU2705304C2 (ru) 2019-11-06
PE20180251A1 (es) 2018-02-02
BR112017022994A2 (pt) 2019-11-19
JP6497760B2 (ja) 2019-04-10
PL3290441T3 (pl) 2020-05-18
CY1122569T1 (el) 2021-01-27
KR20190124350A (ko) 2019-11-04
TWI732757B (zh) 2021-07-11
CN113801225A (zh) 2021-12-17
JP2023025285A (ja) 2023-02-21
TW201710296A (zh) 2017-03-16
AU2016253886A1 (en) 2017-12-14
TW202138389A (zh) 2021-10-16
KR20230173734A (ko) 2023-12-27
US20190270799A1 (en) 2019-09-05
CR20170539A (es) 2018-04-20
CR20200517A (es) 2021-01-12
JP7307446B2 (ja) 2023-07-12
ES2758480T3 (es) 2020-05-05
DK3290441T3 (da) 2020-01-02
PE20230381A1 (es) 2023-03-06
JPWO2016175236A1 (ja) 2018-04-19
KR20220140023A (ko) 2022-10-17
JP2023120374A (ja) 2023-08-29
US11008388B2 (en) 2021-05-18
KR102451786B1 (ko) 2022-10-05
JP6955721B2 (ja) 2021-10-27
IL255293B (en) 2021-10-31
RU2019134410A (ru) 2020-03-03
CL2017002729A1 (es) 2018-06-08
EP3290441A1 (en) 2018-03-07
JP2019141048A (ja) 2019-08-29
CA2983898A1 (en) 2016-11-03
JP7306660B2 (ja) 2023-07-11
ZA201708047B (en) 2020-01-29
PT3290441T (pt) 2019-12-02
IL287291A (en) 2021-12-01
HUE047146T2 (hu) 2020-04-28
EP3290441B1 (en) 2019-10-30
GT201700224A (es) 2019-07-26
CN107531791A (zh) 2018-01-02
WO2016175236A1 (ja) 2016-11-03
SG11201708848TA (en) 2017-11-29
TW202328205A (zh) 2023-07-16
MX2017013894A (es) 2018-03-01
RS59847B1 (sr) 2020-02-28
HRP20192099T1 (hr) 2020-03-06

Similar Documents

Publication Publication Date Title
IL290488A (en) Therapeutic antibodies and their uses
ZA201808160B (en) Bispecific binding proteins and uses thereof
IL287291A (en) A protein that binds to rgma and its use
IL265489B (en) Recombinant binding proteins and their uses
SG10201912199XA (en) Anti-tim-3 antibodies and use thereof
IL246921A0 (en) Binding proteins and their uses
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
EP3541840C0 (en) ANTI-HLA-G ANTIBODIES AND THEIR USE
HK1247091A1 (zh) 治療抗體及其用途
HK1253533A1 (zh) Cd131結合蛋白及其應用
EP3315513A4 (en) Cd154 binding polypeptide and use thereof
IL258863A (en) Integrin-binding peptides and their use
ZA201901942B (en) Nnif and nnif-related peptides and related methods
ZA201901862B (en) Modified factor h binding protein
GB201703049D0 (en) Single-strand binding protein
GB201617925D0 (en) Proteins and uses
GB201519105D0 (en) Antibody polypeptides and uses thereof
GB201517550D0 (en) Antibody polypeptides and uses thereof
AU2014904235A0 (en) Fn14 binding proteins and uses thereof